A judge ruled recently in California that a 5-year-old girl can keep bringing a cannabis-based drug to school to be used during school hours on school property. This is great news for the Adams family who’s daughter has Dravet syndrome.
Dravet syndrome Dravet syndrome is a rare genetic condition that appears during the first year of life with frequent fever-related seizures (febrile seizures). This progresses to other types of seizures and potentially a life-threatening state of continuous seizure activity requiring emergency medical care. The seizures have a profound impact on the patients’ quality of life and before cannabinidoil or CBD oil there have been very little successful longterm treatments.
“CBD is more like maintenance,” Jana Adams said. “The THC actually works like a rescue medication.
It stops (the seizures) within three minutes, and that’s really the life-saving part for us.” It is legal to use the medical marijuana at home in California if you have a doctor’s recommendation. The issue for the Adams family was that their daughter would need this medicine outside of the home.
The critical medication, which has helped cut down seizures to about once a week were creating an issue for the school board because it is derived from marijuana. Thankfully a judge has stepped in to support the family and the medical situation. The full story by Fox News can be found here.
In the United States the FDA recently approved Epidiolex a CBD oil for Dravet syndrome. The research and outcomes are hard to ignore, in Canada there was a recent study completed by sick kids that shows cannabinoids can exert anti-seizure effects and are safe and tolerable in treating paediatric drug resistant epilepsy (DRE).
For one Mother, Laura Weightman, mother of SickKids patient Abigail, 16, this new therapy provides much-needed hope. “This therapy has turned our lives around,” says Weightman. “Abigail’s seizures started at eight months old at a frequency of up to 100 per month. At the time of the trial they had been reduced to 10 – 20 per month with medical and surgical interventions and since participating in this trial, Abigail has only had three seizures in the past year.”
This study used a full spectrum Cannabis product that was donated and formulated by Tilray. The study focused on the dosing and tolerability of a mixed cannabinoid product containing both CBD and THC in children with DRE due to Dravet Syndrome.
This is exciting work as the medical community works to help this group of affected children who until now, had little hope for better health outcomes.